AZ’s cediranib falls short again in ovarian cancer combinationAstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it Share XAZ’s cediranib falls short again in ovarian cancer combinationhttps://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/
AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
AZ’s new cancer drugs drive another stellar quarterAstraZeneca has raised its sales guidance of the year once again as its trio of new cancer drugs Share XAZ’s new cancer drugs drive another stellar quarterhttps://pharmaphorum.com/news/azs-new-cancer-drugs-drive-another-stellar-quarter/
ESMO 2019 – new data could unlock bigger market for PARP inhibitorsAstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as Share XESMO 2019 – new data could unlock bigger market for PARP inhibitorshttps://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
